{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:31:29Z","timestamp":1792276289902,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40265-018-0966-7","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T04:09:43Z","timestamp":1534738183000},"page":"1259-1270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Meropenem\/Vaborbactam: A Review in Complicated Urinary Tract Infections"],"prefix":"10.1007","volume":"78","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"issue":"4","key":"966_CR1","doi-asserted-by":"publisher","first-page":"e020251","DOI":"10.1136\/bmjopen-2017-020251","volume":"8","author":"L Vallejo-Torres","year":"2018","unstructured":"Vallejo-Torres L, Pujol M, Shaw E, et al. Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. BMJ Open. 2018;8(4):e020251.","journal-title":"BMJ Open"},{"issue":"5","key":"966_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269\u201384.","journal-title":"Nat Rev Microbiol"},{"key":"966_CR3","unstructured":"European Association of Urology. Guidelines on urological infections. 2015. https:\/\/uroweb.org\/wp-content\/uploads\/19-Urological-infections_LR2.pdf . Accessed 30 July 2018."},{"key":"966_CR4","unstructured":"US Center for Drug Evaluation and Research. Clinical review(s). 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209776Orig1s000MedR.pdf . Accessed 30 July 2018."},{"key":"966_CR5","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1097\/MJT.0000000000000683","volume":"25","author":"AH Ma","year":"2018","unstructured":"Ma AH, Hughes GJ. Updates in management of complicated urinary tract infections: a focus on multidrug-resistant organisms. Am J Ther. 2018;25:e53\u201366.","journal-title":"Am J Ther"},{"issue":"1","key":"966_CR6","first-page":"1","volume":"6","author":"FS Codjoe","year":"2017","unstructured":"Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci. 2017;6(1):1.","journal-title":"Med Sci."},{"issue":"11","key":"966_CR7","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/AAC.00296-11","volume":"55","author":"KM Papp-Wallace","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943\u201360.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"966_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/00325481.2017.1246055","volume":"129","author":"MS Bader","year":"2017","unstructured":"Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242\u201358.","journal-title":"Postgrad Med"},{"key":"966_CR9","unstructured":"US Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). 2015. https:\/\/www.cdc.gov\/hai\/pdfs\/cre\/CRE-guidance-508.pdf . Accessed 30 July 2018."},{"key":"966_CR10","unstructured":"European Center for Disease Control and Prevention. Carbapenem-resistant Enterobacteriaceae. 2016. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/carbapenem-resistant-enterobacteriaceae-risk-assessment-april-2016.pdf . Accessed 30 July 2018."},{"key":"966_CR11","unstructured":"US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. 2013. https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf . Accessed 30 July 2018."},{"key":"966_CR12","unstructured":"World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017. http:\/\/www.who.int\/news-room\/detail\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed . Accessed 30 July 2018."},{"issue":"4","key":"966_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","volume":"8","author":"D Duin van","year":"2017","unstructured":"van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460\u20139.","journal-title":"Virulence."},{"issue":"1","key":"966_CR14","first-page":"1143","volume":"15","author":"Y Ye","year":"2018","unstructured":"Ye Y, Xu L, Han Y, et al. Mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates. Exp Ther Med. 2018;15(1):1143\u20139.","journal-title":"Exp Ther Med."},{"issue":"9","key":"966_CR15","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","volume":"58","author":"SJ Hecker","year":"2015","unstructured":"Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682\u201392.","journal-title":"J Med Chem"},{"issue":"11","key":"966_CR16","doi-asserted-by":"publisher","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","volume":"61","author":"O Lomovskaya","year":"2017","unstructured":"Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"966_CR17","unstructured":"The Medicines Company. VABOMERE\u2122 (meropenem and vaborbactam): US prescribing Information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209776s001lbl.pdf . Accessed 30 July 2018."},{"issue":"1","key":"966_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs. 2018;78(1):65\u201398.","journal-title":"Drugs."},{"issue":"8","key":"966_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1060028018763288","volume":"52","author":"JC Cho","year":"2018","unstructured":"Cho JC, Zmarlicka MT, Shaeer KM, et al. Meropenem\/vaborbactam, the first carbapenem\/beta-lactamase inhibitor combination. Ann Pharmacother. 2018;52(8):769\u201379.","journal-title":"Ann Pharmacother"},{"key":"966_CR20","unstructured":"Lomovskaya O, Tsivkovski R. Vaborbactam (RPX7009) plus meropenem is active against the newly discovered BKC-1 and FR-1 carbapenemases [abstract no. P1289]. In: 26th ECCMID. 2016."},{"issue":"9","key":"966_CR21","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1128\/AAC.00711-16","volume":"60","author":"M Castanheira","year":"2016","unstructured":"Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the \u03b2-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"966_CR22","unstructured":"US Center for Drug Evaluation and Research. Clinical microbilology\/virology review(s). 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209776Orig1s000MicroR.pdf . Accessed 30 July 2018."},{"key":"966_CR23","unstructured":"Tsivkovski R, Griffith DC, Hecker S, et al. Biochemical characterization of the beta-lactamase inhibitor RPX7009 [abstract no. F-849 plus poster]. In: 52nd ICAAC. 2012."},{"issue":"8","key":"966_CR24","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against Gram-negative clinical isolates in New York city. Antimicrob Agents Chemother. 2015;59(8):4856\u201360.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"966_CR25","doi-asserted-by":"publisher","first-page":"e00567-17","DOI":"10.1128\/AAC.00567-17","volume":"61","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"966_CR26","unstructured":"Castanheira M, Huband MD, Flamm RK, et al. Meropenem-vaborbactam (MER-VAB) tested against contemporary Enterobacteriaceae isolates from USA hospitals [abstract no. 452 plus poster]. In: ASM microbe. 2016."},{"key":"966_CR27","unstructured":"Castanheira M, Mendes RE, Flamm RK, et al. Activity of meropenem\/RPX7009 and comparator agents tested against contemporary Enterobacteriaceae isolates collected from bloodstream infections in USA hospitals [abstract no. C-152 plus poster]. In: 55th ICAAC. 2015."},{"issue":"2","key":"966_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","volume":"52","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Mendes RE, et al. In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. Int J Antimicrob Agents. 2018;52(2):144\u201350.","journal-title":"Int J Antimicrob Agents."},{"issue":"Suppl 1","key":"966_CR29","first-page":"781","volume":"2","author":"MD Huband","year":"2015","unstructured":"Huband MD, Flamm RK, Rhomberg PR, et al. In vitro antibacterial activity of meropenem\/RPX7009, (a carbapenem\/\u03b2-lactamase inhibitor combination) against contemporary Enterobacteriaceae (ENT) isolated from intra-abdominal (IAI) and urinary tract infections (UTI) in the United States [abstract no. 781 plus poster]. Open Forum. Infect Dis. 2015;2(Suppl 1):781.","journal-title":"Infect Dis."},{"key":"966_CR30","unstructured":"Castanheira M, Duncan LR, Deshpande L, et al. Meropenem-vaborbactam activity against Enterobacteriaceae isolates collected during 2014-2015 from European countries [abstract no. P128]. In: 27th ECCMID congress. 2017."},{"key":"966_CR31","unstructured":"Castanheira M, Arends SJR, Deshpande LM, et al. Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016 [abstract no. P1043 plus poster]. In: 28th ECCMID congress. 2018."},{"key":"966_CR32","doi-asserted-by":"crossref","unstructured":"Walsh TJ, Bhowmick T, Darouiche R, et al. Per pathogen outcomes of meropenem-vaborbactam (M-V) versus piperacillin-tazobactam (P-T) in the treatment of adults with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), in TANGO 1, a phase 3 randomized, double-blind, double-dummy trial [abstract no. P1290 plus poster]. In: 27th ECCMID congress. 2017.","DOI":"10.1093\/ofid\/ofw195.07"},{"issue":"1","key":"966_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01904-17","volume":"62","author":"MA Hackel","year":"2018","unstructured":"Hackel MA, Lomovskaya O, Dudley MN, et al. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(1):1\u201310.","journal-title":"Antimicrob Agents Chemother."},{"key":"966_CR34","unstructured":"Yang Q, Zhang G, Xu Y. In vitro activity of meropenem combined with RPX7009 against Enterobacteriaceae producing KPC-type carbapenemases in China [abstract no. P1285]. In: 27th ECCMID congress. 2017."},{"issue":"6","key":"966_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","volume":"17","author":"F Perez","year":"2016","unstructured":"Perez F, El Chakhtoura NG, Papp-Wallace KM, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply \u201cprecision medicine\u201d to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17(6):761\u201381.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"966_CR36","doi-asserted-by":"publisher","first-page":"e01439-17","DOI":"10.1128\/AAC.01439-17","volume":"62","author":"WJ Weiss","year":"2018","unstructured":"Weiss WJ, Pulse ME, Nguyen P, et al. Activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae in a murine model of pyelonephritis. Antimicrob Agents Chemother. 2018;62(1):e01439-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"966_CR37","doi-asserted-by":"publisher","first-page":"e01446-17","DOI":"10.1128\/AAC.01446-17","volume":"62","author":"M Sabet","year":"2017","unstructured":"Sabet M, Tarazi Z, Nolan T, et al. Activity of meropenem-vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae (CRE). Antimicrob Agents Chemother. 2017;62(1):e01446-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"966_CR38","first-page":"S377","volume":"4","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Mendes RE, Duncan LR, et al. Activity of meropenem-vaborbactam against Enterobacteriaceae isolates carrying blaKPC collected worldwide [abstract no. 1234 plus poster]. Open Forum. Infect Dis. 2017;4(Suppl. 1):S377.","journal-title":"Infect Dis."},{"issue":"3","key":"966_CR39","doi-asserted-by":"publisher","first-page":"e02101-17","DOI":"10.1128\/AAC.02101-17","volume":"62","author":"MJ Giddins","year":"2018","unstructured":"Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):e02101-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"966_CR40","doi-asserted-by":"publisher","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):e02097-16.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"966_CR41","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/AAC.01165-15","volume":"59","author":"RM Humphries","year":"2015","unstructured":"Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59(10):6605\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"966_CR42","unstructured":"Lomovskaya O, Tsivkovski R. Vaborbactam (VAB) is not affected by KPC-2 and KPC-3 variants containing Asp179Tyr amino acid substitution that are resistant to ceftazidime (CAZ) potentiation with avibactam [abstract no. 95E plus poster]. In: MAD-ID annual meeting. 2018."},{"key":"966_CR43","unstructured":"Tsivkovski R, Totrov M, Lomovskaya O. Inhibition of KPC-2 by vaborbactam (VAB; formerly RPX7009) does not involve Ser130 (S130) that is important for its inhibition by avibactam (AVI) [abstract no. 373]. In: ASM microbe. 2016."},{"issue":"12","key":"966_CR44","doi-asserted-by":"publisher","first-page":"e01702-17","DOI":"10.1128\/AAC.01694-17","volume":"61","author":"D Sun","year":"2017","unstructured":"Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam: resistance selection, prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):e01702-17.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"966_CR45","doi-asserted-by":"publisher","first-page":"e01969-17","DOI":"10.1128\/AAC.01969-17","volume":"62","author":"M Sabet","year":"2018","unstructured":"Sabet M, Tarazi Z, Rubio-Aparicio D, et al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow fiber model. Antimicrob Agents Chemother. 2018;62(2):e01969-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"966_CR46","unstructured":"US Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209776Orig1s000ClinPharmR.pdf . Accessed 30 July 2018."},{"issue":"Suppl. 1","key":"966_CR47","first-page":"S530","volume":"4","author":"SM Bhavnani","year":"2017","unstructured":"Bhavnani SM, Trang M, Griffith DC, et al. Meropenem\u2013vaborbactam pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses as support for dose selection in patients with normal renal function and varying degrees of renal impairment [abstract no. 1852 plus poster]. Open Forum. Infect Dis. 2017;4(Suppl. 1):S530\u20131.","journal-title":"Infect Dis."},{"key":"966_CR48","unstructured":"Griffith D, Sabet M, Tarazi Z, et al. Pharmacodynamics of vaborbactam when administered in combination with meropenem [abstract no. Sunday-194]. In: ASM microbe. 2017."},{"key":"966_CR49","unstructured":"Trang M, Griffith DC, Bhavnani SM, et al. Population pharmacokinetics (PPK) of mereopenem and vaborbactam in healthy volunteers and infected patients [abstract no. SUNDAY-192]. In: ASM microbe. 2017."},{"issue":"3","key":"966_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02103-17","volume":"62","author":"CM Rubino","year":"2018","unstructured":"Rubino CM, Bhavnani SM, Loutit JS, et al. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother. 2018;62(3):1\u201310.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"966_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clinthera.2017.12.007","volume":"40","author":"JM Kidd","year":"2018","unstructured":"Kidd JM, Avery LM, Asempa TE, et al. Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated Y-site administration. Clin Ther. 2018;40(2):261\u20139.","journal-title":"Clin Ther"},{"issue":"8","key":"966_CR52","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788\u201399.","journal-title":"JAMA"},{"key":"966_CR53","unstructured":"Shorr A, Loutit J, Dudley M, et al. Meropenem-vaborbactam (M-V): clinical outcomes by comorbidity severity in TANGO 1 [abstract no. 306 plus poster]. In: ASM microbe. 2017."},{"issue":"Suppl. 1","key":"966_CR54","first-page":"S542","volume":"4","author":"A Mathers","year":"2017","unstructured":"Mathers A, Hope W, Kaye KS, et al. Meropenem-vaborbactam: outcomes in subjects with renal impairment in phase 3 studies TANGO I and II [abstract no. 1879 plus poster]. Open Forum. Infect Dis. 2017;4(Suppl. 1):S542.","journal-title":"Infect Dis."},{"key":"966_CR55","unstructured":"Shorr A, Dufour S, Loutit J, et al. Hospital and ICU length of stay (LOS) with meropenem-vaborbactam (M-V) versus piperacillin-tazobactam (P-T) in complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) in TANGO 1 [abstract no. 94E plus poster]. In: MAD-ID annual meeting. 2018."},{"issue":"Suppl. 1","key":"966_CR56","doi-asserted-by":"publisher","first-page":"S534","DOI":"10.1093\/ofid\/ofx163.1392","volume":"4","author":"KS Kaye","year":"2017","unstructured":"Kaye KS, Vazquez J, Mathers A, et al. Clinical outcomes of serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) in TANGO II, a phase 3, randomized, multinational, open-label trial of meropenem-vaborbactam (M-V) vs. best available therapy (BAT) [abstract no. 1862 plus poster]. Open Forum Infect Dis. 2017;4(Suppl. 1):S534\u20135.","journal-title":"Open Forum Infect Dis."}],"updated-by":[{"DOI":"10.1007\/s40265-018-0974-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0966-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T16:20:14Z","timestamp":1661790014000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0966-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0966-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"20 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Meropenem\/Vaborbactam: A Review in Complicated Urinary Tract Infections.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sohita Dhillon is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}